Bruker

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI Life Science segment includes enabling life science tools based on magnetic resonance technology. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. The BSI CALID segment includes the design and distribution of life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. The BSI Nano segment offers x-ray instruments that use electromagnetic radiation with wavelengths to determine the characteristics of matter and the three-dimensional (3D) structure of molecules. The BEST segment consists of conducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research, and other applications. The company was founded by Gunther Laukien in 1960 and is headquartered in Billerica, MA.

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

Bruker Corporation continues to demonstrate attractive economic characteristics. The firm is creating value for shareholders by recycling capital back into growth investments at superb rates of return.

Bruker: Fundamental, Market Generated Data Corroborate Buy Thesis

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2023, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company's common stock over a two-year period commencing on May 15, 2023. The share repurchase authorization permits shares to be repurchased under open market purchases, accelerated share repurchases, or pursuant to trading plans intended to qualify under Rule 10b5-1 of the S.

Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board Declares Quarterly Dividend

Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.

Bruker's (BRKR) New Buyout to Advance Digital Transformation

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that is has closed the acquisition of ZONTAL Inc. (www.zontal.io), an innovative platform provider for the digital transformation of the analytical laboratory, and for integrated biopharma technical data solutions. This acquisition further strengthens Bruker BioSpin's Integrated Data Solutions (IDS) software division, which includes Mestrelab Research (www.mestrelab.com), Arxspan (www.arxspan.com) and Optimal (.

Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions

Bruker Corporation (NASDAQ:BRKR ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Justin Ward - Senior Director of IR & Corporate Development Frank Laukien - Chairman, President & CEO Gerald Herman - EVP & CFO Conference Call Participants John Sourbeer - UBS Puneet Souda - SVB Securities Josh Waldman - Cleveland Research Daniel Arias - Stifel Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Daniel Brennan - Cowen Brandon Couillard - Jefferies Matt Sykes - Goldman Sachs Operator Good day, and welcome to the Bruker Corporation First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.

Bruker Corporation (BRKR) Q1 2023 Earnings Call Transcript

Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.

Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook

Bruker (BRKR) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.49 per share a year ago.

Bruker (BRKR) Beats Q1 Earnings and Revenue Estimates

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2023. First Quarter 2023 Financial Results Bruker's revenues for the first quarter of 2023 were $685.3 million, an increase of 15.2% compared to $595.0 million in the first quarter of 2022. In the first quarter of 2023, revenues increased 17.6% organically year-over-year. Growth from acquisitions was 2.1%, while foreign currency translation had a negative.

Bruker Reports First Quarter 2023 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2023 financial results before market opening on Thursday, May 4, 2023. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2023 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentat.

Bruker Announces Date and Time of First Quarter 2023 Earnings Release and Webcast

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker (BRKR) Earnings Expected to Grow: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Bruker (BRKR) is a Top Growth Stock for the Long-Term

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?

ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC 2023), Bruker announces innovations for NMR spectroscopy in life science, pharma, and cleantech research to enable discoveries in functional structural biology, drug discovery, and battery research. Bruker launches the Ascend Evo 400 new standard 400 MHz NMR magnet with a liquid helium hold-time of one year to reduce cost of ownership and enhance operational convenience.

Bruker Advances NMR Magnet Portfolio, Innovates in Industrial Solutions

COPENHAGEN, Denmark--(BUSINESS WIRE)---- $BRKR #BRKR--At the 33rd European Congress of Clinical Microbiology & Infectious Diseases (www.eccmid.org), Bruker Corporation (Nasdaq: BRKR) announced its latest innovations for user-friendly, best-in-class diagnostic solutions for routine clinical microbiology and infection diagnostics laboratories. 1.

Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel

BRKR's Canopy Biosciences collaborates with Enable Medicine to bring advanced spatial analysis pipelines to the Canopy CellScape System for high-plex spatial biology.

BRKR's Canopy Biosciences Partners With Enable Medicine

ST. LOUIS & MENLO PARK, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Canopy Biosciences, a Bruker Company, and Enable Medicine, today announced a partnership to provide Enable Medicine's advanced analysis pipelines for spatial omics data with the Canopy CellScape™ system for quantitative high-plex spatial biology.

Canopy Biosciences and Enable Medicine Announce Partnership to Bring Advanced Spatial Analysis Pipelines to the ChipCytometry Platform

Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

Bio-Rad Laboratories

QIAGEN

This year the National Institutes of Health is set to request its biggest budget yet for 2024, on the heels of its previous biggest budget in 2023. As the COVID-19 pandemic fades from view, labs will switch back to other avenues of research, often funded by the NIH.

The 3 Most Promising Biotech Stocks to Buy Now

Bruker (BRKR) extends support to the expansion efforts of the UK Science community by providing 1.2 GHz Avance NMR spectrometers.

Bruker (BRKR) Receives 1.2 GHz NMR System Orders From the UK

COVENTRY, United Kingdom--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker announces that the United Kingdom is expanding its fundamental research infrastructure with recent orders for two 1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometers for the University of Warwick and the University of Birmingham. Each institution already has a Bruker 1.

Bruker Announces Two 1.2 GHz NMR Systems Orders from the UK

CHICAGO--(BUSINESS WIRE)---- $BRKR #BRKR--At the 19th US HUPO, Bruker Corporation (Nasdaq: BRKR) announced important bioinformatics launches for 4D-Proteomics on the timsTOF platform: A novel de novo sequencing algorithm was developed in collaboration with Rapid Novor Inc., using over 1.7 million PASEF data-points to improve accuracy and speed for immunopeptidomics in real-time.

Bruker Launches de novo Sequencing for Immunopeptidomics, Library-Free dia-PASEF, Mass Dynamics Knowledge Visualization

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York City Thursday, March 2, 2023, at 9:30 a.m. Eastern Time Cowen 43rd Annual Health Care Conference in Boston, MA Monday, March 6, 2023, at 2:10 p.m.

Bruker Corporation to Present at Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 17, 2023 to stockholders of record as of March 1, 2023. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.

Bruker Announces Quarterly Dividend

Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.

News for Bruker Stock (BRKR)